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Transgenic analyses have defined two MyoD enhancers in mammals, the core enhancer and distal regulatory region (DRR);
these enhancers exhibit complementary activities and together are sufficient to recapitulate MyoD expression in developing
and mature skeletal muscle. DRR activity is restricted to differentiated muscle and persists postnatally, suggesting an
important role in maintaining MyoD expression in myocytes and muscle fibers. Here, we use targeted mutagenesis in the
mouse to define essential functions of the DRR in its normal chromosomal context. Surprisingly, deletion of the DRR
resulted in reduced MyoD expression in all myogenic lineages at E10.5, at least 1 day prior to detection of DRR activity in
limb buds and branchial arches of transgenic mice. At later embryonic and fetal stages, however, no defect in MyoD
expression was observed, indicating that the DRR is dispensable for regulating MyoD during muscle differentiation.
Expression analyses in wild-type and Myf-5 mutant embryos also indicate that the DRR is not an obligate target for Myf-5-
and Pax-3-dependent regulation. In contrast to embryonic and fetal stages, deletion of the DRR resulted in a pronounced
reduction in MyoD mRNA levels in adults, showing a functional requirement for DRR activity in mature muscle. These
data reveal essential and redundant functions of the DRR and underscore the importance of loss-of-function enhancer
analyses for understanding cis transcriptional circuitry. © 2002 Elsevier Science (USA)
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In vertebrate embryos, commitment of cells to the skel-
etal muscle lineage requires either MyoD or Myf-5, two
members of the muscle-specific basic helix–loop–helix
transcription factor family. In the absence of these muscle
regulatory factors (MRFs), myogenesis fails to occur (Rud-
nicki et al., 1993), and presumptive myogenic cells are
diverted to nonmuscle lineages (Tajbakhsh et al., 1996;
Kablar et al., 1999). During somite development, MyoD and
Myf-5 are activated in a precise temporal and spatial pattern
in response to signaling molecules produced by the noto-
chord, neural tube, surface ectoderm, and lateral plate
mesoderm (reviewed by Borycki and Emerson, 2000). Al-
though considerable progress has been made in identifying
these signaling proteins, which include Sonic hedgehog
(Shh), Wnt proteins, and BMPs and their antagonists, little
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All rights reserved.is known of how MyoD and Myf-5 transcription is initiated
and maintained in response to these signals.
Previous gain- and loss-of-function experiments have
begun to define the hierarchical relationship between
MyoD and other transcriptional regulatory factors ex-
pressed in somites. For example, MyoD expression is abro-
gated in the body muscles of mouse embryos mutant for
both Myf-5 and the paired box transcription factor, Pax-3,
indicating that these factors function upstream of MyoD
(Tajbakhsh et al., 1997). In addition, a number of transcrip-
tion factors and cofactors, including Pax-3, Six1, Dach2, and
Eya2, have been shown to activate MyoD when overex-
pressed in somite explant cultures (Maroto et al., 1997;
Heanue et al., 1999). It remains to be determined, however,
whether any of these factors regulate MyoD through direct
transcriptional interactions with MyoD regulatory se-
quences. Mutations in Myf-5 (Tajbakhsh et al., 1996; Grass
et al., 1996; Tajbakhsh et al., 1997), Pax-3 (Franz et al.,
1993; Tajbakhsh et al., 1997; Borycki et al., 1999b), and
Paraxis (Burgess et al., 1996; Wilson-Rawls et al., 1999), for
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example, disrupt somite patterning, raising the possibility
that effects on MyoD expression are secondary to their roles
in somite morphogenesis. Indeed, in Myf-5 and Pax-3 mu-
tant embryos, muscle precursor cells exhibit migratory
defects and may not be positioned properly to receive
myogenic signals (Tajbakhsh et al., 1996, 1997).
As an essential step toward defining the regulatory path-
ways that govern myogenic determination and MyoD acti-
vation, we have used transgenic mouse analysis to charac-
terize mammalian enhancer sequences that control MyoD
expression. These studies showed that 24 kb of human
MyoD 5 flanking sequence is sufficient to recapitulate
endogenous MyoD expression in mouse embryos (Chen et
al., 2001), as well as in normal and injured adult skeletal
muscles (unpublished observations). Two muscle-specific
enhancers with distinct but overlapping specificity have
been characterized within MyoD flanking sequence in hu-
mans and mice. A highly conserved core enhancer sequence
approximately 20 kb upstream of MyoD is sufficient for
early MyoD activation in somites, limb buds, and branchial
arches (Goldhamer et al., 1995; Faerman et al., 1995; Kablar
et al., 1998). Linker-scanner mutagenesis of this 258-bp
sequence has identified multiple cis elements required for
its activity, including an enhancer region specifically re-
quired in myotomal lineages that may represent a target for
Myf-5-dependent regulation of MyoD (Kucharczuk et al.,
1999; unpublished observations). The core enhancer also
exhibits MRF-independent transcriptional activity (Kablar
et al., 1999), likely reflecting a role in initiating MyoD
expression in a subpopulation of muscle progenitor cells
early in the myogenic program. However, the core enhancer
is not sufficient to maintain MyoD expression in differen-
tiated skeletal muscle, being down-regulated in fetal and
neonatal muscle and essentially inactive in adult muscle
(Faerman et al., 1995; unpublished observations).
Five kilobases upstream of MyoD is a second enhancer,
the distal regulatory region (DRR), which is unrelated in
sequence to the core enhancer and exhibits largely comple-
mentary activity in transgenic mice (Tapscott et al., 1992;
Goldhamer et al., 1995; Asakura et al., 1995; Kablar et al.,
1998; Chen et al., 2001). DRR activity is entirely MRF-
dependent (Kablar et al., 1999) and is restricted to differen-
tiated skeletal muscle in vivo (Kablar et al., 1997), which is
reflected as a significant delay in DRR-driven transgene
expression in several sites of myogenesis relative to the
endogenous MyoD gene (Asakura et al., 1995). Unlike the
core enhancer, the DRR remains active in adult muscle,
showing a similar expression profile as the endogenous
MyoD gene (Hughes et al., 1993). Collectively, these data
indicate that the core enhancer and DRR have distinct
activation and maintenance functions, respectively, that
collaborate to establish the dynamic pattern of MyoD
expression in embryonic and adult skeletal muscle (Chen et
al., 2001).
Although transgenic studies are a powerful means to
characterize activities of transcriptional regulatory se-
quences, transgenesis is inherently limited in its ability to
assess required functions of such elements, as restricted
sequences are used that are inserted at heterologous
genomic loci (reviewed by Fiering et al., 1999). To circum-
vent these limitations, we have used targeted mutagenesis
in mice to determine the essential functions and regulatory
relationships of the MyoD enhancers in their normal chro-
mosomal context. Here, we report the consequences of
targeted deletion of the DRR. Replacement of the DRR with
the neo-positive selection marker (DRRneo allele) resulted in
a dramatic reduction in MyoD expression in all muscle
lineages and at all pre- and postnatal stages tested. Removal
of the neo cassette by Cre-mediated recombination (DRRloxP
allele), however, produced stage-specific defects in MyoD
expression. Analysis of E9.75 embryos showed that the
DRR is dispensable for the initiation of MyoD expression in
branchial arches and somites. Surprisingly, however, MyoD
expression was reduced in E10.5 DRRloxP/loxP embryos, re-
vealing an essential DRR function earlier in the myogenic
program than expected from previous transgenic work. The
DRR is also required to maintain MyoD expression in adult
skeletal muscle, as MyoD levels were reduced by approxi-
mately 65% in DRRloxP/loxP leg muscles. In contrast, MyoD
expression was not affected in differentiating muscle fibers
of embryos and fetuses. In addition, in Myf-5 mutant
embryos, Pax-3-dependent recovery of MyoD expression
(Tajbakhsh et al., 1997) occurred with normal kinetics in
the absence of the DRR, showing that the DRR is not an
obligate target for Pax-3-dependent MyoD expression.
These data reveal essential and redundant DRR functions in
developing and mature skeletal muscle.
MATERIALS AND METHODS
Targeted Mutagenesis and Generation of Chimeric
Mice
A 1.9-kb ApaI/XhoI genomic fragment (5870 to 4000 relative
to the MyoD transcriptional start site) containing the 714-bp DRR
(Tapscott et al., 1992) was targeted for deletion by homologous
recombination. Approximately 11 kb of 129/SvJ mouse genomic
DNA containing the DRR was isolated by screening a gt11 library
(Clontech), cloned into pBluescript KS (Stratagene), and mapped
by restriction enzyme digests using standard methods. The 1.9-kb
fragment was replaced with a PGKneo-positive selection cassette
flanked by loxP sites (from ploxPneo-1; kindly provided by Dr.
Marisa Bartolomei), cloned in a 3 to 5 orientation to avoid
possible read-through transcription into the MyoD gene. The
targeting construct (Fig. 1) has 5 and 3 homology arms of approxi-
mately 5 and 3 kb, respectively, as well as an HSVtk-negative
selection cassette adjacent to the 5 homology arm.
Approximately 4  107 GS1 129/SvJ ES cells (Incyte) were
electroporated with 40 g of NotI-linearized targeting vector (800
V, 3 F) and plated on a monolayer of mitomycin C (Sigma)-treated,
G418-resistant primary embryonic fibroblasts on 0.1% gelatin
(Sigma)-coated tissue culture dishes in ES media [15% FBS (Hy-
clone), 100 units/ml Penicillin (Gibco), 100 g/ml Streptomycin
(Gibco), 2 mM L-glutamine (Gibco), 100 M nonessential amino
acids (Gibco), 10 mM Hepes (Gibco), 100 M -mercaptoethanol
(Sigma), and 103 units/ml ESGRO (Calbiochem) in high glucose
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DMEM (Gibco)]. After 24 h, selection media was added [ES media
containing 200 g/ml Geneticin (LTI) and 1 M ganciclovir] and
cells were cultured for 8–12 days. Resistant ES colonies were
expanded and targeted clones identified by Southern analysis of
XbaI-digested DNA with a radioactive probe to a 1.1-kb XbaI/
EcoRI fragment that lies outside of the 5 homology arm (Fig. 1).
Targeting was confirmed by Southern analysis of XhoI-digested
DNA with a HindIII/StuI 3 probe (data not shown). Targeting
frequency was approximately 1 in 150 G418/ganciclovir-resistant
clones.
To remove the neo cassette, targeted ES clones were electropo-
rated with 25 g of the Cre expression plasmid pBS185 (Sauer and
Henderson, 1990; kindly provided by Dr. Brian Sauer) and plated at
clonal density. Individual colonies were expanded and screened by
Southern blotting with flanking probes to test for the loss of the
PGKneo gene and to verify the fidelity of the recombined locus.
PCR was used to verify lack of integration of the excised neo
cassette and the Cre plasmid.
Targeted ES clones, both with (DRRneo) and without (DRRloxP) the
neo cassette, were injected into C57 blastocysts by the University
of Pennsylvania Transgenic and Chimeric Mouse Facility. Chi-
meric mice were crossed to C57Bl/6J mice, and germline transmis-
sion was assessed by Southern analysis of tail DNA.
Mouse Breeding and Embryo Genotyping
For in situ and Northern analyses, heterozygous DRR mutant
mice were mated and litters harvested at various stages with noon
of the day of plug considered E0.5. Somite number was used for
more accurate staging of embryos from E9.75 to E11.5, according to
Rugh (1991). To obtain DRRloxP;Myf-5 double mutant embryos,
DRRloxP/loxP mice were interbred with Myf-5/ mice (Braun et al.,
1992) to generate DRR/loxP;Myf-5/ mice, which were subse-
quently crossed to DRRloxP/loxP mice to generate DRRloxP/loxP;Myf-5/
mice. Embryos used for analysis were generated by intercrossing
DRR/loxP;Myf-5/ mice, or by crossing DRR/loxP;Myf-5/ and
DRRloxP/loxP;Myf-5/ mice.
DNA was isolated from yolk sacs and genotyping performed by
Southern hybridization as described above.
Whole-Mount in Situ Hybridization
E9.75 to E12.5 embryos were fixed in freshly prepared 4%
paraformaldehyde in PBS, and processed for in situ hybridization
with a digoxigenin-labeled MyoD RNA probe as previously de-
scribed (Chen et al., 2001). Embryos within a comparison group
were processed simultaneously and developed for identical times to
allow direct comparisons of staining intensities. In order to detect
small differences in staining intensities, embryos were inspected
frequently during the staining process, and occasionally stained in
a fourfold dilution of NBT/BCIP and X-phosphate (Roche).
RNA Isolation and Northern Analysis
Tissues were quick-frozen in liquid nitrogen, and total RNA was
isolated by either the LiCl-urea method [Auffray and Rougeon,
1980; E11.5 embryos, decapitated (to increase the representation of
muscle-specific mRNAs) E15.5 embryos, and 7 day neonatal pooled
forelimb and hindlimb muscles] or the guanidine isothiocyanate-
CsCl method (Chirgwin et al., 1979; adult tibialis anterior, gastroc-
nemius, or pooled hindlimb muscles) using a Polytron homo-
genizer for tissue dissociations. Total RNA (5–10 g) was
electrophoresed on formaldehyde agarose gels, transferred to Gene-
Screen nylon membrane (NEN), and hybridized with a 32P-labeled
full-length mouse MyoD cDNA probe (Radprime kit; Gibco) in
PerfectHyb Plus (Sigma) by using standard methods. After exposing
blots to phosphor screens and scanning with a Storm Scanner 860
(Molecular Dynamics), blots were reprobed with an 800-bp EcoRI
fragment from the rat GAPDH cDNA and rescanned. MyoD
hybridization signals were quantified by using ImageQuant soft-
ware (Molecular Dynamics) and normalized to GAPDH. Analyses
were performed at least three times at each time point.
Photomicroscopy
Embryo whole-mount images were photographed by using a
Hamamatsu C5810 color video camera and Nikon SMZU stereomi-
croscope under dark-field illumination. Identical light and camera
conditions were used to capture images of littermate embryos
processed side by side for in situ hybridization. Images were
captured and assembled by using Adobe Photoshop and Illustrator,
respectively.
RESULTS
Generation of DRR Mutant ES Cells and Chimeric
Mice
To define essential functions of the mouse DRR, the
minimal genomic element shown to direct muscle-specific
expression in transgenic mice was deleted (Asakura et al.,
1995). This 1.9-kb ApaI/XhoI fragment contains the origi-
nally defined 714-bp DRR, which directs muscle-specific
expression in cell culture (Tapscott et al., 1992) but has not
been assayed in vivo. A standard replacement strategy was
used whereby a PGKneo cassette was inserted in place of
the 1.9-kb DRR fragment (Fig. 1A). As cases of long-range
transcriptional inhibition by the neo cassette have been
well-documented (reviewed by Olson et al., 1996; Fiering et
al., 1999), the neo cassette was flanked by loxP sites to
allow its excision by Cre-mediated recombination (Sauer
and Henderson, 1988). A single transcriptionally inert loxP
site (Arango et al., 1999) was present at the DRR locus
following Cre recombination.
Chimeric mice were generated from DRR-targeted ES
cells, and germ line transmission was achieved for both
DRRneo and DRRloxP mutations. Mutant lines were main-
tained by interbreeding to C57Bl/6J mice, and are in a
mixed B6, 129 background. Crosses of heterozygous mice
generated viable and fertile DRRneo and DRRloxP homozy-
gous null adult offspring at expected Mendelian ratios (data
not shown). In contrast, MyoD null mice produced by a
heterozygous cross exhibit reduced survival at weaning
(Rudnicki et al., 1992).
DRRneo Mice Exhibit a Pronounced Decrease in
MyoD Expression in All Myogenic Populations
Whole-mount in situ hybridization and Northern analy-
sis revealed a dramatic decrease in MyoD expression in
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DRRneo embryos and adult muscle. Embryos exhibited a
generalized reduction in MyoD expression in all muscle
populations and at all developmental stages examined
(E10.5–E15.5), although the timing of MyoD expression was
not affected (data not shown). Quantitative Northern blots
of RNA isolated from E15.5 embryos and neonatal and adult
muscle revealed an 80% reduction in MyoD mRNA levels.
Induction of MyoD expression in crush-injured muscle also
was severely curtailed (data not shown).
Cre-Mediated Excision of the Neo Cassette
Restores Near-Normal Levels of MyoD Expression
in Embryos
The dramatic effect on MyoD expression of the DRRneo
mutation could result from the deletion of the DRR, inhibi-
tory effects of the neo cassette, or both. To distinguish
between these possibilities, MyoD expression was analyzed
in DRRloxP embryos by northern hybridization (Fig. 2).
FIG. 1. (A) Targeting strategy for the mouse DRR. The 1.9-kb ApaI/XhoI fragment, which contains the DRR, was replaced by a floxed
PGKneo cassette. The targeting vector (pDRRneotk) contains a 5-kb 5 homology arm delineated by the EcoRI and ApaI restriction sites,
and a 3-kb 3 homology arm delineated by the XhoI and HindIII restriction sites (ApaI and XhoI sites were destroyed during subcloning).
The structure of the locus following homologous recombination (DRRneo) and Cre-mediated excision of the neo cassette (DRRloxP) are
shown. Diagnostic bands generated using the 5 probe on XbaI-digested DNA are indicated above the locus diagrams. A 3 probe was also
used to verify the integrity of the locus following homologous recombination. (B) Representative Southern blot using the 5 probe on
XbaI-digested DNA. DNA was isolated from offspring of a cross of heterozygous DRRloxP (lanes 1–7) and DRRneo (lanes 8–14) mice. All
genotypic classes were generated at expected Mendelian ratios.
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Interestingly, MyoD mRNA levels were similar in wild-
type, heterozygous, and homozygous null embryos at E11.5
and E15.5, showing that the severe, constitutive expression
defect observed in DRRneo mutants is the result of inhibi-
tion by the neo cassette, and not deletion of the DRR. Thus,
the DRR is sufficient (Hughes et al., 1993; Asakura et al.,
1995; Kablar et al., 1997) but not required to maintain
MyoD expression in differentiating embryonic and fetal
muscles.
Whole-mount in situ hybridization was performed on
DRRloxP embryos to determine whether the DRR is required
in a specific myogenic cell population that would not be
discernible by Northern analysis. MyoD expression was
observed in epaxial and hypaxial myotome subdomains, in
limb buds, and in branchial arches (Fig. 3), showing no
lineage-specific defects in MyoD expression. Interestingly,
however, a relatively small but consistent decrease in
staining intensity was observed in all myogenic populations
at E10.5. The decrease in MyoD expression in the limb buds
and branchial arches (Figs. 3B and 3F) reveals that the DRR
is necessary but not sufficient (Asakura et al., 1995; Chen et
al., 2001) for normal MyoD expression in these myogenic
populations at this stage. In the mouse, MyoD mRNA is
first detected by whole-mount in situ hybridization in the
mandibular arch and interlimb somites at E9.75 (Tajbakhsh
et al., 1997; Chen et al., 2001). We compared MyoD expres-
sion in wild-type and DRRloxP/loxP embryos at E9.75 to
determine whether the initiation of MyoD expression was
impaired by deletion of the DRR. No consistent difference
in MyoD expression was observed between wild-type and
DRR null embryos based on both staining intensity and the
craniocaudal extent of somite expression (Figs. 3A and 3E),
indicating that the earliest induction of MyoD expression is
not dependent on the DRR.
MyoD expression in the myotome is thought to be
directed by the complementary activities of the core en-
hancer and DRR; core enhancer transgenes are active in the
medial and lateral aspects of the myotome (Faerman et al.,
1995; Goldhamer et al., 1995; Kablar et al., 1998), whereas
DRR transgenes are strongly expressed only in the central
myotome at E10.5 and E11.5 (Asakura et al., 1995; Kablar et
al., 1998; Chen et al., 2001). Surprisingly, however, the
DRR is not required for MyoD expression in the central
myotome at these stages (Figs. 3B, 3C, 3F, and 3G), suggest-
ing that additional cis elements direct expression to this
region normally, or can provide this function in the absence
of the DRR.
The DRR Is Not Required for Pax-3-Dependent
MyoD Expression
Embryos mutant for both Myf-5 and Pax-3 fail to activate
MyoD in the body proper, and are essentially devoid of
trunk and limb musculature (Tajbakhsh et al., 1997). In
embryos mutant only for Myf-5, MyoD expression in myo-
tomes is delayed by approximately 2 days, eventually
recovering through a Pax-3-dependent mechanism
(Tajbakhsh et al., 1997). To determine whether the DRR is
essential for Pax-3-dependent MyoD expression, embryos
mutant for both Myf-5 and the DRR were analyzed by in
situ hybridization. Deletion of the DRR did not affect the
timing or the extent of Pax-3-dependent MyoD expression
(Fig. 4). As expected, MyoD expression in myotomes was
delayed in Myf-5/ (data not shown) and DRR/loxP;Myf-5/
embryos, with recovery beginning in the lateral myotome
by E11.5 (Fig. 4B; Tajbakhsh et al., 1997). Similarly, MyoD
expression was observed in the lateral myotomal domains
of DRRloxP/loxP;Myf-5/ embryos at E11.5 (Fig. 4C). Staining
was slightly reduced in DRRloxP/loxP;Myf-5/ embryos rela-
tive to DRR/loxP;Myf-5/ embryos (Figs. 4B and 4C), reflect-
ing the minor quantitative effect of the DRR mutation that
was more apparent at E10.5 (Fig. 3). By E12.5, both heterozy-
gous and null DRRloxP embryos exhibited robust MyoD ex-
pression comparable to that of Myf-5/ embryos (Figs. 4D–
FIG. 2. DRRloxP/loxP embryos exhibit wild-type MyoD mRNA levels at E11.5 and E15.5. Total RNA was isolated from wild-type and DRR
mutant E11.5 embryos and decapitated E15.5 fetuses, and consecutively hybridized with MyoD- and GAPDH-specific, 32P-labeled probes.
MyoD hybridization signals were quantified and normalized to GAPDH levels by using a Storm Scanner 860 and ImageQuant software.
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4F), although developing trunk musculature was disorganized,
as reported previously (Figs. 4E and 4F; Braun et al., 1992). We
conclude that the DRR is not required for Pax-3-dependent
MyoD expression in Myf-5 mutant embryos.
The DRR Is Essential for Normal MyoD Expression
in Adults
We tested the requirement for DRR function in postnatal
muscle by measuring MyoD mRNA levels in neonatal and
adult leg muscles. Deletion of the DRR had only a slight
effect (average decrease of 15%) on MyoD expression in
pooled 7-day neonatal limb muscles (Figs. 5A and 5B). In
contrast, MyoD mRNA levels were reduced by 65% in the
adult tibialis anterior muscle (Figs. 5A and 5B). A similar
reduction was observed in the gastrocnemius and pooled
hindlimb muscles of 24-week adults (data not shown). The
stage-specificity of the DRRloxP phenotype strongly suggests
that the pronounced effect on MyoD expression is not a
consequence of disrupted chromatin structure or the pres-
ence of a loxP sequence at the MyoD locus. These data
demonstrate that the DRR is required to maintain normal
levels of MyoD expression in adult muscle and indicate that
distinct regulatory mechanisms control MyoD expression
in embryonic and mature musculature.
DISCUSSION
An inherent limitation of transgenic studies is their
inability to elucidate required functions of transcriptional
elements in a native chromosomal context, due to the
FIG. 3. Whole-mount in situ hybridization for MyoD mRNA in wild-type (A–D) and DRRloxP/loxP (E–H) littermates from E9.75 to E12.5.
MyoD expression was indistinguishable in wild-type and mutant embryos at E9.75 (A, E). Weak staining was observed in the branchial
arches (red arrows) and to a similar craniocaudal extent in interlimb somites. Black arrows indicate the position of the forelimb buds. At
E10.5 (B, F), a decrease in staining intensity was consistently observed in DRRloxP/loxP embryos [compare forelimb buds (black arrows) and
branchial arches (red arrows) in B and F], although the spatiotemporal patterning of MyoD expression was preserved. Prolonged development
revealed staining in the branchial arches of DRRloxP/loxP embryos (data not shown). By E11.5 (C, G), MyoD was expressed at near wild-type
levels in DRRloxP/loxP embryos and staining was observed in all major myogenic populations. At E12.5 (D, H), MyoD staining intensity and
pattern were indistinguishable in wild-type and DRRloxP/loxP embryos.
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necessarily limited sequences used as transgenes and their
integration at heterologous sites in the genome. While
reporter gene assays in transgenic mice have shown that
the combined activities of the core enhancer and DRR
are sufficient to regulate MyoD expression in embryonic
and adult skeletal muscle, whether these enhancers
serve unique and necessary functions and possible redun-
dant networks governing MyoD transcription had not been
explored previously. In the present study, targeted mu-
tagenesis revealed both essential and redundant DRR func-
tions.
Long-Range Disruption of MyoD Expression by the
Neo Cassette
Replacement of the DRR with the neo cassette resulted
in a dramatic reduction in MyoD expression to approxi-
mately 20% of wild-type levels at all embryonic and post-
natal stages tested. Comparable inhibition of MyoD expres-
sion also was observed when the neo cassette replaced the
core enhancer, approximately 20 kb upstream of MyoD
(unpublished observations). Because long-range interference
of gene expression by positive selection cassettes such as
FIG. 4. Deletion of the DRR did not affect Pax-3-dependent rescue of MyoD expression in Myf-5 mutant embryos. (A) Embryos
heterozygous for both DRRloxP and Myf-5 exhibit MyoD expression throughout the mediolateral extent of the myotome at E11.5 (black
arrows), comparable to wild-type embryos. (B, C) At E11.5, DRR/loxP; Myf-5/ and DRRloxP/loxP; Myf-5/ embryos show weak MyoD
expression in the ventrolateral myotomes of interlimb somites (black arrows), representing an early phase of Pax-3-dependent compensa-
tion. A slight decrease in MyoD staining was observed in DRRloxP/loxP embryos (most evident by comparing regions posterior to the black
arrows in B and C), which is unrelated to the Myf-5 mutant genotype (see Fig. 3). MyoD expression in limb buds (red arrows) and branchial
arch-derived myogenic cells (arrowheads) of E11.5 embryos was essentially unaffected by the Myf-5 mutation, consistent with previous
observations (Tajbakhsh et al., 1997; Kablar et al., 1997). (D–F) By E12.5, MyoD expression levels were normal in myotomal muscles of
Myf-5 mutant embryos both in the presence (E) and absence (F) of a functional DRR allele. Disorganization of trunk musculature in Myf-5
mutant embryos (arrows) is the result of rib defects associated with the Myf-5m1 allele (Braun et al., 1992).
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neo have been observed in a number of enhancer- and
gene-targeting studies (reviewed by Olson et al., 1996;
Fiering et al., 1999), neo was flanked by loxP sequences to
allow its removal by Cre-mediated recombination. At most
embryonic stages, removal of the neo cassette restored
MyoD expression essentially to wild-type levels (see below),
demonstrating that insertion of neo, and not deletion of the
DRR, was responsible for the constitutive reduction in
MyoD mRNA levels.
Genetic studies have shown that MyoD heterozygotes,
which express 50% of normal MyoD mRNA levels, can
support normal myogenesis in the absence of Myf-5 (Rud-
nicki et al., 1992, 1993). In contrast, one wild-type Myf-5
allele is not sufficient to support normal myogenesis in a
MyoD mutant background, indicating different threshold
requirements for these key regulators of myogenesis (Rud-
nicki et al., 1993). Preliminary analysis has shown that late
gestational DRRneo/neo;Myf-5/ fetuses exhibit histologi-
cally normal skeletal muscle (unpublished data), suggesting
that 20% of normal MyoD mRNA levels are sufficient to
support embryonic myogenesis. Additional analysis, in-
cluding further titration of MyoD levels by combining
MyoD knockout and DRRneo alleles, will provide important
insights into MyoD dosage requirements for embryonic
myogenesis. Kaul et al. (2000) recently developed a viable
Myf-5loxP knockout strain that lacks rib defects characteris-
tic of the original mutation. Thus, MyoD knockout,
DRRneo, and DRRloxP alleles will provide an allelic series
with which to study genetic interactions between MyoD
and Myf-5 in regulating postnatal muscle growth and regen-
eration (see Seale and Rudnicki, 2000).
The DRR Is Not Required in Differentiating
Embryonic Skeletal Muscle
Based on transgenic studies, a simple prediction was that
DRRloxP embryos would exhibit reduced MyoD expression
in differentiating muscle, since expression of DRRlacZ
transgenes are restricted to differentiating muscle and core
enhancer activity is down-regulated as skeletal muscle
differentiates and matures (reviewed in Chen et al., 2001).
In the somite, for example, core enhancer activity predomi-
nates in the younger myocytes of the medial and lateral
myotomal domains, but is down-regulated in older myo-
cytes of the central myotome (Faerman et al., 1995; Kablar
et al., 1998; see Ordahl et al., 2000 and Cinnamon et al.,
2001 for discussions of myotome formation). In contrast,
DRR activity is largely complementary, and is the only
known MyoD regulatory element that exhibits robust ac-
tivity in the central myotome (Asakura et al., 1995; Kablar
et al., 1998; Chen et al., 2001). Deletion of the DRR,
however, did not reduce MyoD expression in the central
myotome at E10.5 and E11.5 relative to other myogenic
populations, nor was expression significantly diminished in
differentiating muscle at any embryonic stage tested. These
results demonstrate that the DRR is dispensable for MyoD
expression in differentiating skeletal muscle, and suggest
that redundant transcriptional networks regulate MyoD in
embryos. Surprisingly, although DRR transgene activity is
not detected in limb buds and branchial arches at E10.5
(Asakura et al., 1995), DRRloxP/loxP embryos exhibited a
consistent decrease in MyoD expression in somites, limb
buds, and branchial arches at this stage. Thus, the DRR
plays an essential role early in the myogenic program, likely
cooperating with the core enhancer and perhaps other
elements to confer wild-type expression levels. The DRR
does not regulate the initiation of MyoD expression, how-
ever, as deletion of the DRR did not affect MyoD expression
at E9.75, the stage at which MyoD expression is first
detected by in situ hybridization.
The DRR Is Dispensable for Myf-5- and Pax-3-
Dependent MyoD Regulation
Myf-5 and Pax-3 function in parallel genetic pathways to
regulate MyoD (Tajbakhsh et al., 1997; Kablar et al., 1997;
Borycki et al., 1999a), although their specific roles have not
been elucidated. Both Myf-5 (Tajbakhsh et al., 1996) and
Pax-3 (Bober et al., 1994; Williams and Ordahl, 1994;
Daston et al., 1996; Tremblay et al., 1998) regulate cell
migration of myogenic precursors, raising the possibility
that their effects on MyoD expression are an indirect
consequence of improper positioning of muscle precursor
cells relative to myogenic signals (Daston et al., 1996;
Tajbakhsh et al., 1996, 1997). Alternatively, these transcrip-
tion factors may play a more direct role in MyoD transcrip-
tional control, a notion consistent with Pax-3 overexpres-
sion studies (Maroto et al., 1997), and the fact that MyoD
induction by Shh in somite explants is dependent on Myf-5
(Borycki et al., 1999a). In addition, both the core enhancer
and the DRR contain multiple E-boxes (Tapscott et al.,
1992; Goldhamer et al., 1995; Chen et al., 2001) and a
potential binding site for the paired DNA binding domain of
Pax factors (Phelan and Loeken, 1998). That deletion of the
DRR did not phenocopy the MyoD expression defect in
Myf-5 mutant embryos indicates that the DRR is not an
obligate target for Myf-5 regulation of MyoD. Interestingly,
deletion of a conserved E-box in the core enhancer results in
a pattern of transgene expression that closely resembles
endogenous MyoD expression in Myf-5 mutant embryos
(Kucharczuk et al., 1999; unpublished observations) sug-
gesting that Myf-5-dependent regulation of MyoD may
function through the core enhancer, a possibility being
addressed by targeted mutagenesis.
In Myf-5 mutant embryos, MyoD expression in the trunk
is entirely dependent on Pax-3 (Tajbakhsh et al., 1997). The
DRR apparently can mediate Pax-3-dependent expression,
as a DRR transgene was expressed in the myotomes of
Myf-5 mutant embryos (Kablar et al., 1997). Targeted dele-
tion of the DRR, however, did not affect the timing or
extent of Pax-3-dependent MyoD expression, showing that
the DRR is not an essential Pax-3 target and that other
sequences can also mediate Pax-3-dependent regulation. A
likely candidate is the core enhancer, as a core enhancer
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transgene was also expressed in Myf-5 mutants (Kablar et
al., 1998). In this regard, it will be important to determine
how two enhancers of unrelated sequence and distinct
activities can function in the Pax-3-dependent transcrip-
tional pathway, and whether Pax-3 directly binds these
enhancers or functions by regulating genes involved in cell
migration (reviewed by Birchmeier and Brohmann, 2000) or
other processes upstream of MyoD expression.
The DRR Is Required to Maintain Normal MyoD
Expression Levels in Adult Skeletal Muscle
Deletion of the DRR resulted in a 65% reduction in
MyoD expression in the adult tibialis anterior, gastrocne-
mius, and pooled hindlimb muscles. It is likely that this
mutation affects MyoD transcription in muscle fibers
themselves, as MyoD is not expressed in quiescent satellite
cells (Maley et al., 1994; Smith et al., 1994; Yablonka-
Reuveni and Rivera, 1994; Cornelison and Wold, 1997), and
few myoblasts are present in mature skeletal muscle (Snow,
1977). The present study did not address whether all muscle
fiber types were affected similarly by the DRR mutation. In
this regard, the endogenous MyoD gene as well as DRR
transgenes are expressed at higher levels in fast glycolytic
fibers than in slow fibers (Hughes et al., 1993); a require-
ment for the DRR in a subset of fast fiber types could
potentially explain a reduction in MyoD mRNA levels of
the magnitude observed. Nevertheless, these data demon-
strate that maintenance of normal MyoD levels in mature
skeletal muscle depends on DRR function, and point to
differences in transcriptional pathways or compensatory
mechanisms operative in immature and mature muscle.
One similarity with regulation of MyoD in embryos, how-
ever, is a reliance on multiple regulatory pathways, as
deletion of the DRR did not abrogate MyoD expression in
adult muscle.
A 1.9-kb DRR-containing fragment was targeted, as this
is the minimum sequence that has been tested for DRR
activity in transgenic mice (Asakura et al., 1995). Although
the precise DRR sequences required for MyoD expression in
adult muscle and early embryos remain to be delineated, we
favor the view that the required regulatory information is
contained within the originally defined 714-bp DRR (Tap-
scott et al., 1992). First, the 714-bp DRR exhibits muscle
specificity in cell culture (Tapscott et al., 1992) and con-
tains several motifs for known muscle regulatory factors
(Tapscott et al., 1992; Chen et al., 2001). Second, it shows
extended blocks of sequence conservation between humans
and mice, whereas other sequences within the 1.9-kb frag-
ment exhibit minimal conservation (Chen et al., 2001).
Third, the 714-bp DRR sequence is subject to chromatin
modification by MyoD in cell culture (Gerber et al., 1997),
providing a possible means for maintaining MyoD gene
expression by autoregulation (see Thayer et al., 1989). In
this latter regard, it will be interesting to determine
whether chromatin modification of the DRR occurs in vivo
and whether this modification is MyoD-dependent.
Enhancer Redundancy
Taken together with previous transgenic data, the present
results indicate that redundancy is an integral aspect of the
transcriptional circuitry regulating MyoD expression. We
are currently investigating whether other enhancers exist
with DRR-like specificity, or whether the core enhancer,
despite its apparently distinct activities, can compensate in
the absence of the DRR. Using similar targeting strategies,
gene regulation by redundant cis elements has also been
documented for -globin (Fiering et al., 1995), HoxD (Za-
kany et al., 1997; Beckers and Duboule, 1998), and the T
cell receptor variable region genes (Monroe et al., 1999),
raising the possibility that gene regulation by functionally
FIG. 5. Deletion of the DRR significantly reduces MyoD expres-
sion in adult muscle. (A) Representative northern analysis of MyoD
expression in skeletal muscle of postnatal DRRloxP/loxP mice. Total
RNA was isolated from pooled forelimb and hindlimb muscles of
neonates and pooled tibialis anterior muscles from 12-week-old
mice, hybridized to MyoD and GAPDH-specific probes, and quan-
tified as in Fig. 2. Northern analysis of 24-week adult gastrocne-
mius and pooled hindlimb muscles gave similar results (data not
shown). (B) Quantification of MyoD expression in neonatal and
adult muscle. MyoD northern hybridization signals in DRRloxP
muscle were normalized to wild-type values, and each bar repre-
sents the average of four independent experiments. Error bars, 
SEM.
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interchangeable cis motifs is a common theme in develop-
ment, as suggested by transgenic studies in a variety of
species (reviewed by Arnone and Davidson, 1997; Dover,
2000). Redundancy of regulatory regions such as the DRR
could result from the presence of multiple enhancers that
can each act as targets for transcription factor mediators of
a particular developmental pathway. Alternatively, func-
tionally equivalent but distinct signaling and transcrip-
tional pathways may each activate transcription through a
unique DNA target. In this regard, enhancer-targeted mice
will be valuable reagents to directly link Shh, Wnt, and
other signaling pathways with transcriptional responses
that regulate MyoD expression.
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